	US 12,227,577 B2
	Combination of a PD-1 antagonist, an ATR inhibitor and a platinating agent for the treatment of cancer
Marat Alimzhanov, Wellesley, MA (US); Patricia Soulard, Lexington, MA (US); Frank Zenke, Darmstadt (DE); Heike Dahmen, Darmstadt (DE); Astrid Zimmermann, Muehltal (DE); Andreas Schroeder, Heidelberg (DE); Keyvan Tadjalli Mehr, Heidelberg (DE); and Martin Falk, Roedermark (DE)
Assigned to Merck Patent GMBH, Darmstadt (DE)
Appl. No. 17/280,035
Filed by Merck Patent GMBH, Darmstadt (DE)
PCT Filed Sep. 26, 2019, PCT No. PCT/EP2019/076116 § 371(c)(1), (2) Date Mar. 25, 2021, PCT Pub. No. WO2020/064971, PCT Pub. Date Apr. 2, 2020.
Claims priority of provisional application 62/736,699, filed on Sep. 26, 2018.
Prior Publication US 2022/0048997 A1, Feb. 17, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 31/497 (2006.01); A61K 31/555 (2006.01); A61P 35/00 (2006.01); G01N 33/68 (2006.01)

CPC C07K 16/2827 (2013.01) [A61K 31/497 (2013.01); A61K 31/555 (2013.01); A61P 35/00 (2018.01); G01N 33/6866 (2013.01); G01N 2333/56 (2013.01); G01N 2333/565 (2013.01); G01N 2333/57 (2013.01); G01N 2800/52 (2013.01)]

10 Claims

1. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a PD-1 antagonist, an ATR inhibitor and a platinating agent,

wherein the PD-1 antagonist is selected from the group consisting of avelumab, nivolumab, pembrolizumab, atezolizumab, durvalumab and cemiplimab, and

wherein the ATR inhibitor is selected from the group consisting of Compound 1, or a pharmaceutically acceptable salt thereof, Compound 2, or a pharmaceutically acceptable salt thereof, Compound 3, or a pharmaceutically acceptable salt thereof, Compound 4, or a pharmaceutically acceptable salt thereof, and Compound 5, or a pharmaceutically acceptable salt thereof.